undamentalytics Newsletter
Sign in

Amneal Pharmaceuticals, Inc. cash flow statement

In fiscal 2025, Amneal Pharmaceuticals, Inc.'s operations generated $340m of cash; it spent $70.1m on capital projects, leaving free cash flow of $270m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations115234250237924265346295340201
Depreciation and amortisation29426463606168666357—
Stock-based pay001682221283227283236
Capital spending12395834756484643527073
Free cash flow−8139167−4532319419302243270128
Free cash flow after stock pay−8139−0−67302166−1327621523892
Dividends paid20137518300——————
Share buybacks0——————————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: AMRX vs RPRXAMRX vs JAZZAMRX vs ELAN

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Amneal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Amneal Pharmaceuticals, Inc.